MARKET

EGRX

EGRX

Eagle Pharmaceut
NASDAQ
26.42
-2.18
-7.62%
After Hours: 26.42 0 0.00% 16:49 09/30 EDT
OPEN
28.66
PREV CLOSE
28.60
HIGH
28.72
LOW
26.41
VOLUME
414.20K
TURNOVER
0
52 WEEK HIGH
58.25
52 WEEK LOW
26.21
MARKET CAP
350.98M
P/E (TTM)
14.95
1D
5D
1M
3M
1Y
5Y
Enalare Secures BARDA Award Of $50M For ENA-001 In Drug Overdose
Benzinga · 5d ago
Eagle, Enalare get up to $50.3M US contract to develop ENA-001 for community drug overdose
Eagle Pharmaceuticals (NASDAQ:EGRX) <a href="https://...
Seekingalpha · 5d ago
BRIEF-Eagle Pharma And Enalare Therapeutics Announce Additional Award Worth Up To $50 Mln From BARDA To Advance Intramuscular Formulation Of ENA-001
BRIEF-Eagle Pharma And Enalare Therapeutics Announce Additional Award Worth Up To $50 Mln From BARDA To Advance Intramuscular Formulation Of ENA-001
Reuters · 5d ago
Eagle Pharmaceuticals And Enalare Therapeutics Announce Additional Award Worth Up To $50M From BARDA To Advance An Intramuscular Formulation of ENA-001
-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depression --   --
Benzinga · 5d ago
Eagle Pharmaceuticals-Backed Enalare Secures Up to $50.3 Million in BARDA Funding for Acute Respiratory Depression Drug
Eagle Pharmaceuticals-Backed Enalare Secures Up to $50.3 Million in BARDA Funding for Acute Respiratory Depression Drug
MT Newswires · 5d ago
New Strong Sell Stocks for September 9th
EGRX, TWTR and PLAY have been added to the Zacks Rank #5 (Strong Sell) List on September 9, 2022.
Zacks · 09/09 10:36
Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present...
GlobeNewswire · 08/30 20:05
Eagle Pharma did not infringe on Endo’s vasopressin patents – appeals court
Eagle Pharmaceuticals (NASDAQ:EGRX) announced Thursda...
Seekingalpha · 08/18 17:33
More
About EGRX
Eagle Pharmaceuticals, Inc. is a pharmaceutical company. The Company's products include Ryanodex, Bendeka, Belrapzo, Treakisym, Pemfexy, Barhemsys and Byfavo. Ryanodex is used for malignant hyperthermia. EP-4104 Ryanodex (dantrolene sodium) is used for the treatment of organophosphate exposure. Belrapzo, Bendeka and Treakisym are used for chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Pemfexy is an IV-administered cancer agent indicated for locally advanced or metastatic non-small cell lung cancer and mesothelioma. Its oncology and CNS/metabolic critical care pipeline includes product candidates that addresses underserved therapeutic areas across multiple disease states. Its vasopressin is an A-rated generic alternative to Vasostrict, which is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It is engaged in clinical trials for CAL02, an approach to the treatment of severe bacterial pneumonia.

Webull offers kinds of Eagle Pharmaceuticals Inc stock information, including NASDAQ:EGRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EGRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EGRX stock methods without spending real money on the virtual paper trading platform.